Bausch + Lomb’s SWOT analysis: stock faces mixed signals on growth plan

Bausch + Lomb Corporation (NYSE:BLCO), a medical supplies and devices company in the healthcare sector, has unveiled an ambitious three-year strategic plan that promises significant growth and margin expansion. The company’s new Long Range Plan sets targets that exceed current market expectations, though recent performance across its business segments presents a mixed picture for investors evaluating the stock.

Strategic vision through 2028

The company’s newly announced Long Range Plan outlines a comprehensive strategy to achieve mid-to-high single-digit sales growth and double-digit earnings per share growth through 2028. The plan includes a substantial expansion of EBITDA margins by 600 basis points over this period, representing one of the more aggressive margin improvement targets in the medical supplies and devices sector.

Management has maintained its guidance for fiscal year 2025, signaling confidence in near-term execution while simultaneously setting higher expectations for the years ahead. The strategic plan’s targets surpass both analyst estimates and market consensus figures, suggesting management believes the company has identified significant operational improvement opportunities.

The margin expansion component of the plan stands out as particularly ambitious. A 600 basis point improvement in EBITDA margins over three years would require substantial operational efficiency gains, potential pricing power, or favorable shifts in product mix toward higher-margin offerings.

Recent operational performance

The company’s third quarter 2025 results revealed divergent performance across its three main business segments. The Pharma division demonstrated notable strength, exceeding expectations and suggesting robust demand for the company’s pharmaceutical products. This division’s performance has become a key driver of overall company results.

The Surgical segment delivered results that aligned with analyst forecasts, indicating stable execution in this portion of the business. Meeting expectations in surgical products suggests the company maintains its competitive position in this market, though without notable outperformance.

Vision Care, representing a significant portion of the company’s business, fell short of both analyst estimates and market consensus despite recording solid growth of 6%. This underperformance in a core segment raises questions about competitive dynamics and market share trends in the vision care market. The gap between the segment’s growth rate and expectations suggests either heightened competition or potential market share losses.

Segment dynamics and market positioning

The Pharma division’s strength reflects the company’s position in pharmaceutical eye care products. Strong performance in this segment may indicate successful product launches, market share gains, or favorable pricing dynamics. The pharmaceutical business typically offers higher margins than other segments, making its outperformance particularly valuable for the company’s overall margin expansion goals.

The Surgical segment’s in-line performance suggests stability in a market that includes products for cataract surgery and other ophthalmic procedures. This segment faces competition from established medical device manufacturers and requires continuous innovation to maintain market position.

Vision Care, which includes contact lenses and lens care products, operates in a highly competitive market with significant players. The segment’s underperformance relative to expectations, despite achieving 6% growth, indicates the company may face challenges in this market. Consumer preferences, competitive pricing, and market saturation could all contribute to the performance gap.

Financial outlook and earnings trajectory

Analysts project earnings per share of $0.81 for fiscal year 2026, representing significant growth from the company’s recent loss of $0.62 per share over the last twelve months. An InvestingPro tip notes that analysts predict the company will be profitable this year, marking a crucial inflection point. The company generated $5.21 billion in revenue over the last twelve months with 7.85% growth, while maintaining a strong gross profit margin of 60.62%. EBITDA reached $724 million, providing the foundation for the planned margin expansion initiatives.

The earnings trajectory depends on successful execution across multiple fronts. Revenue growth must materialize as planned, margin expansion initiatives must deliver results, and the company must navigate foreign exchange headwinds that have been incorporated into updated financial models.

The company’s market capitalization currently stands at $5.74 billion, positioning it as a mid-sized player in the medical supplies and devices sector. According to InvestingPro analysis, the stock is currently trading above its Fair Value, suggesting investors are pricing in optimistic expectations for the company’s strategic plan execution. The platform’s comprehensive financial health assessment rates BLCO as "GOOD" overall, with particularly strong price momentum scores. This scale provides resources for research and development while maintaining growth potential that larger, more mature companies might lack.

Industry context and competitive landscape

The medical supplies and devices industry maintains a positive outlook, supported by demographic trends including aging populations in developed markets and increasing healthcare access in emerging economies. Ophthalmic products benefit from rising rates of vision correction needs and increasing prevalence of eye diseases associated with aging and digital device usage.

The competitive landscape includes large diversified healthcare companies as well as specialized ophthalmic product manufacturers. Success requires continuous innovation, strong relationships with eye care professionals, and effective marketing to consumers in certain product categories.

Foreign exchange trends have been incorporated into analyst models, reflecting the global nature of the medical devices business. Currency fluctuations can significantly impact reported results for companies with substantial international operations.

Bear Case

Can the company overcome Vision Care segment challenges?

The Vision Care segment’s underperformance presents a significant concern for the company’s overall growth trajectory. Despite achieving 6% growth, the segment fell short of analyst expectations and market consensus, suggesting deeper issues than temporary headwinds. The contact lens and lens care market has become increasingly competitive, with multiple manufacturers vying for market share through pricing, product innovation, and marketing investments.

If competitive pressures continue to intensify, the company may face difficult choices between defending market share through pricing actions that pressure margins, or maintaining pricing discipline at the risk of further share losses. The segment’s performance becomes particularly critical given its size within the overall business portfolio. Sustained underperformance in Vision Care could offset strength in other segments and make achieving the Long Range Plan targets significantly more challenging.

Will ambitious margin expansion targets prove achievable?

The company’s goal of expanding EBITDA margins by 600 basis points through 2028 represents an aggressive target that requires flawless execution across multiple operational levers. Achieving this level of margin improvement typically requires a combination of factors including favorable product mix shifts, operational efficiency gains, purchasing leverage, and potentially pricing power.

The risk lies in the execution complexity of simultaneously driving revenue growth while implementing margin improvement initiatives. Companies sometimes face trade-offs between growth and margins, particularly in competitive markets. If the Vision Care segment continues to face competitive pressures, the company might need to increase promotional spending or accept lower pricing, both of which would work against margin expansion goals. Manufacturing efficiency improvements and overhead leverage can contribute to margin gains, but a 600 basis point improvement over three years requires substantial progress on multiple fronts.

Bull Case

Can Pharma division strength drive overall performance?

The Pharma division’s strong third quarter performance demonstrates the company possesses competitive advantages in pharmaceutical eye care products. This segment typically commands higher margins than other business lines, making its outperformance particularly valuable for overall profitability. If the division continues to exceed expectations, it could become an increasingly important driver of both revenue growth and margin expansion.

Pharmaceutical eye care products benefit from several favorable dynamics including aging demographics, increasing prevalence of chronic eye conditions, and limited generic competition for newer products. The company’s strong performance suggests its product portfolio resonates with eye care professionals and patients. Continued success in this segment could offset challenges elsewhere in the business and provide the profit engine needed to fund investments in other areas.

Will operational improvements deliver planned margin expansion?

The company’s Long Range Plan reflects management’s confidence in identified opportunities for operational improvement. A 600 basis point EBITDA margin expansion over three years, while ambitious, may be achievable through a combination of initiatives. Manufacturing efficiency improvements, supply chain optimization, and overhead leverage as revenue grows could all contribute meaningful margin gains.

The company’s scale provides opportunities for purchasing leverage and operational efficiency that smaller competitors might lack. If management successfully executes on identified improvement initiatives while maintaining revenue growth momentum, the margin expansion could materialize as planned. Success would validate the Long Range Plan and potentially drive significant earnings growth, as margin improvement drops directly to the bottom line. The reiteration of 2025 guidance suggests management has visibility into near-term execution, which could build confidence in longer-term targets.

SWOT Analysis

Strengths

• Strong performance in Pharma division exceeding expectations
• Comprehensive Long Range Plan with clear targets through 2028
• Diversified business model across Pharma, Surgical, and Vision Care segments
• Position in growing ophthalmic products market
• Scale advantages in manufacturing and distribution

Weaknesses

• Vision Care segment underperformance relative to expectations
• Execution risk associated with ambitious margin expansion targets
• Dependence on successful new product launches
• Exposure to foreign exchange fluctuations
• Competition in core Vision Care markets

Opportunities

• Positive industry outlook driven by demographic trends
• Significant EBITDA margin expansion potential of 600 basis points
• Double-digit EPS growth trajectory through 2028
• Market share gains in pharmaceutical eye care products
• Operational efficiency improvements across manufacturing and supply chain
• Aging global population increasing demand for eye care products

Threats

• Intensifying competition in Vision Care segment
• Risk of not achieving ambitious Long Range Plan targets
• Foreign exchange headwinds impacting international operations
• Pricing pressures in competitive product categories
• Potential market share losses in contact lens business
• Execution challenges in implementing multiple improvement initiatives simultaneously

Analyst Targets

Barclays Capital Inc. maintained an Equal Weight rating with a price target of $17.00 on November 14th, 2025.

Barclays Capital Inc. maintained an Equal Weight rating with a price target of $17.00 on October 31st, 2025.

Barclays Capital Inc. maintained an Equal Weight rating with a price target of $16.00 on October 27th, 2025.

This analysis is based on information available from October 2025 through November 2025.

InvestingPro: Smarter Decisions, Better Returns

Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on BLCO. Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore BLCO’s full potential at InvestingPro.

Should you invest in BLCO right now? Consider this first:

Investing.com’s ProPicks, an AI-driven service trusted by over 130,000 paying members globally, provides easy-to-follow model portfolios designed for wealth accumulation. Curious if BLCO is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the next level.

To evaluate BLCO further, use InvestingPro’s Fair Value tool for a comprehensive valuation based on various factors. You can also see if BLCO appears on our undervalued or overvalued stock lists.

These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.